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ABSTRACT
Dysregulation of receptor tyrosine kinases (RTKs) contributes to several aspects 
of oncogenesis including drug resistance. In melanoma, distinct RTKs have been 
involved in BRAF inhibitors (BRAFi) resistance, yet the utility of RTKs expression 
pattern to identify intrinsically resistant tumors has not been assessed. Transcriptional 
profiling of RTKs and integration with a previous classification, reveals three robust 
subtypes in two independent datasets of melanoma cell lines and one cohort of 
melanoma samples. This classification was validated by Western blot in a panel of 
patient-derived melanoma cell lines. One of the subtypes identified here for the first 
time displayed the highest and lowest expression of EGFR and ERBB3, respectively, 
and included BRAF-mutant tumors all intrinsically resistant to BRAFi PLX4720, as 
assessed by analysis of the Cancer Cell Line Encyclopedia pharmacogenomic study and 
by in vitro growth inhibition assays. High levels of EGFR were detected, even before 
therapy, in tumor cells of one of three melanoma patients unresponsive to BRAFi. 
Use of different pharmacological inhibitors highlighted the relevance of PI3K/mTOR 
signaling for growth of this PLX4720-resistant subtype. Our results identify a specific 
molecular profile of melanomas intrinsically resistant to BRAFi and suggest the PI3K/
mTOR pathway as a potential therapeutic target for these tumors.
INTRODUCTION
The discovery of the BRAFV600E substitution as the 
most common genetic event in melanoma [1] rapidly led 
to the clinical development of selective ATP-competitive 
RAF kinase inhibitors (i.e. Vemurafenib, Dabrafenib) 
targeting the mutant BRAF protein [2, 3]. These two drugs 
gained FDA approval, based on evidence for significant 
improvement in response rates and in progression free 
survival, compared to chemotherapy, in randomized phase 
III trials [4, 5]. Despite these remarkable clinical results, 
acquired resistance invariably develops in most patients, 
including those showing an initial strong regression of 
tumor burden [4, 6]. Furthermore, approximately 1 in 
5 patients with BRAF mutant melanoma shows progression 
at first assessment during treatment, due to intrinsic/
primary resistance in their tumors [6, 7] indicating that 
the mutational status of the target oncogene is insufficient 
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to predict responsiveness to therapy. The identification 
of molecular features associated with primary resistance 
to mutant BRAF targeting will enable identification of 
melanoma patients likely to fail treatment. To this end, 
gene expression profiling provides powerful means of 
classifying tumors based on their underlying biology 
[8–11]. In melanoma, two divergent major subtypes, 
consistently identified by several authors [12–16], could be 
classified according to the “Melanoma Phenotype-Specific 
Expression” (MPSE) signature [17]. This signature 
includes the melanocyte master regulator microphthalmia-
associated transcription factor (MITF) and many of its 
known targets [18]. Low expression of MITF and MITF-
regulated genes and high expression of genes involved 
in motility and invasiveness, including AXL, defines the 
subtype named invasive, while the proliferative one is 
defined by opposite expression of these genes [17]. Indeed, 
we have previously shown that AXL is highly expressed, at 
the protein level, in human melanoma cell lines and clinical 
samples which lacks expression of MITF and of MITF-
targets [19]. The antagonistic MITF/AXL transcriptional 
profile was recently linked to intrinsic resistance to RAF 
and MAPK pathway inhibitors [20]. Thus, higher levels of 
MITF and correlated genes were found in BRAF mutant 
tumors sensitive to the BRAF inhibitor (BRAFi) PLX4720 
and to the MEK inhibitor (MEKi) AZD6244, whereas 
resistant lines were associated to high NF-κB activity and 
expression of AXL and correlated genes [20].
Subtype-specific expression of key signaling proteins 
like AXL and other RTKs is also central to the signaling 
pathways inherently available to a given melanoma cell-
type. Several studies proposed elevated signaling of single 
RTKs as a mechanism of BRAFi resistance [21–28]. So 
far, however, the potential role of RTK profiling as a 
classification tool to discriminate BRAFi-resistant and 
-susceptible tumors has not been evaluated.
In this study we assessed whether the expression 
pattern of RTK genes could stratify melanomas in different 
groups. By integrating the RTK classification with the 
previously identified MPSE phenotypes [17], we derived 
a robust classification of melanoma tumors in three 
subtypes that was validated in both cell lines and clinical 
samples. This classification led to the identification of a 
new melanoma subtype displaying intrinsic resistance 
to targeted therapy against mutant BRAF. Moreover, 
we provide evidence of PI3K/mTOR signaling pathway 
dependency of such intrinsically resistant cells.
RESULTS
Melanoma subtypes identification in CCLE 
dataset
We hypothesized that different melanoma subtypes 
could exist on the basis of the gene expression pattern 
of RTK genes. To assess our hypothesis we applied a 
class discovery approach (Figure 1A) to gene expression 
data of 58 melanoma cell lines (Supplementary Table 1) 
included in the Cancer Cell Line Encyclopedia (CCLE) 
[29]. We selected 177 probe sets representing 57 unique 
RTKs. Based on the gene expression barcode, 64 probe 
sets, mapping on 34 unique RTKs and expressed in at 
least 5% of samples, were used to perform hierarchical 
clustering (HC) (Figure 1B). We found two major clusters 
composed of 12 and 46 samples and characterized by 
distinct expression patterns of RTK genes. In particular, 
the two clusters were marked by mutually exclusive 
expression of ERBB3 and EGFR (Figure 1B), thus 
they were named EGFRHIGH/ERBB3LOW and EGFRLOW/
ERBB3HIGH. Additionally, consensus hierarchical 
clustering (CHC) was applied and we observed that HC 
and CHC were highly concordant in assigning samples to 
the two subtypes, indicating a good robustness of these 
classes (Supplementary Figure 1A). Finally, according to 
silhouette analysis, 56 samples had a positive silhouette 
score and were representative of their cluster assignment 
(Supplementary Figure 1B), while two samples 
with a negative silhouette score were classified as 
“undetermined”.
We next asked how our newly identified RTK 
subtypes compared with the invasive and proliferative 
phenotypes. For this purpose we used the MPSE signature 
[17] to predict the phenotype of the 58 melanoma 
cell lines included in CCLE. This prediction assigned 
22 samples to the invasive phenotype and 25 to the 
proliferative one; the remaining 11 cell lines could not be 
assigned to any phenotype (Supplementary Figure 1C). 
A clear and robust distinction in two groups of the 47 
classified cell lines was confirmed by HC and CHC using 
the MPSE signature (Figure 1C and Supplementary 
Figure 1D). Silhouette analysis proved that all samples 
were correctly classified (Supplementary Figure 1E). 
Comparing the RTK and MPSE classifications we found 
that all EGFRHIGH/ERBB3LOW samples were included in the 
invasive phenotype while EGFRLOW/ERBB3HIGH samples 
were invasive or proliferative (Figure 1C). Therefore, 
we combined RTK and MPSE subtypes leading to the 
following classification in three main subtypes: EGFRHIGH/
ERBB3LOW-Invasive; EGFRLOW/ERBB3HIGH-Invasive; 
EGFRLOW/ERBB3HIGH-Proliferative. Samples with an 
undetermined classification by RTK or MPSE were not 
assigned to any of the three subtypes and were excluded 
from subsequent analyses.
This new classification was obtained by sequential 
stratification of samples using two distinct gene lists. 
To retrieve an integrated gene signature, able to directly 
discriminate the three subtypes, we applied the ClaNC 
algorithm and we identified a 210-gene signature (named 
hereafter RTK/MPSE) (Supplementary Table 2) as the 
minimal set of genes with lowest classification error rate 
(error rate in five-fold cross-validation = 0%). Among 
RTK genes, both EGFR and ERBB3 were included in this 
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Figure 1: Melanoma subtypes identification by class discovery in the CCLE dataset. (A) Workflow of bioinformatics 
analysis. (B) RTKs expression of 58 melanoma cell lines grouped by hierarchical clustering. Samples are separated in two major clusters 
named EGFRHIGH/ERBB3LOW (blue) and EGFRLOW/ERBB3HIGH (red). Black bars highlight EGFR and ERBB3 probe sets. (C) Hierarchically 
clustered heatmap showing the expression of MPSE genes in the 47 samples with a defined phenotype: light green, Invasive; yellow, 
Proliferative. RTK labels are shown for comparison. (D) Heatmap of the hierarchical clustering using the RTK/MPSE signature: EGFRHIGH/
ERBB3LOW-Invasive (green); EGFRLOW/ERBB3HIGH-Invasive (violet); EGFRLOW/ERBB3HIGH-Proliferative (orange). The number of 
clustered samples, as detailed in the text, is forty-five. The 210 genes of the RTK/MPSE signature are grouped into three highly correlated 
clusters: 1, light-blue; 2, pink; 3, brown.
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signature. The ability of the new RTK/MPSE signature 
to discriminate the three subtypes was assessed by HC 
(Figure 1D) and the accuracy of such classification was 
confirmed. These 210 genes clustered in three major 
groups of highly correlated genes (Figure 1D and 
Supplementary Table 2). We performed functional analysis 
of these gene-clusters to identify biological pathways 
distinguishing our melanoma subtypes (summarized in 
Table 1). EGFRLOW/ERBB3HIGH-Proliferative subtype 
was defined by MITF, MITF-regulated genes and 
other genes involved in melanocyte development and 
pigmentation signaling (gene-cluster 1). EGFRHIGH/
ERBB3LOW-Invasive melanomas could be distinguished 
from EGFRLOW/ERBB3HIGH-Invasive by down-regulation 
of genes involved in antigen presentation pathways and 
coding for HLA class II antigens and their transcriptional 
regulators (gene-cluster 2) and for higher expression of 
genes associated to regulation of epithelial-mesenchymal 
Table 1: Summary of the main features of RTK/MPSE subtypes. Upwards arrows represent activation 
or high expression, downwards arrows inhibition or low expression. The number of arrows indicate the 
strenght of the feature
EGFRHIGH/
ERBB3LOW-Invasive
EGFRLOW/
ERBB3HIGH-Invasive
EGFRLOW/ERBB3HIGH-
Proliferative
Subtype frequency [n, (%)] in
CCLE 11 (24.4) 9 (20.0) 25 (55.6)
Meta-Cell 25 (14.1) 25 (14.1) 127 (71.8)
Meta-Clinical 46 (12.8) 36 (10.0) 277 (77.2)
Pathways defined by RTK/MPSE genes (activation or inhibition)
Eumelanin biosynthesis ↓↓ ↓ ↓↓
Melanocyte development and pigmentation 
signaling ↓↓ ↓ ↓↓
Antigen presentation ↓↓ ↓↓ ↓
Allograft rejection signaling ↓↓ ↓↓ ↓
OX40 signaling ↓↓ ↓↓ ↓
Hepatic fibrosis / hepatic stellate cell 
activation ↓↓ ↓ ↓↓
Human embryonic stem cell pluripotency ↓↓ ↓ ↓↓
Regulation of the epithelial-mesenchymal 
transition ↓↓ ↓ ↓↓
RTKs expression (high or low expression)
AXL ↓↓ ↓↓ ↓↓
EGFR ↓↓ ↓ ↓↓
EPHA2 ↓ ↓ ↓
ERBB3 ↓↓ ↓↓ ↓↓
MERTK ↓↓ ↓↓ ↓
PDGFRA ↓ ↓ ↓
PDGFRB ↓ ↓ ↓
PLX4720 sensitivity
Resistant ↓ ↓
Intermediate ↓ ↓
Sensitive ↓ ↓
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transition, cellular movement, constituent of extracellular 
matrix and growth factors (gene-cluster 3). These 
later genes were down-regulated in the EGFRLOW/
ERBB3HIGH-Proliferative subtype. These results indicate 
that expression of genes involved in relevant biological 
pathways such as melanoma development, differentiation, 
immunity and metastatic behavior allows dissection 
of melanoma heterogeneity in three clearly separated 
subtypes. Furthermore, this classification led to the 
discovery of the EGFRHIGH/ERBB3LOW-Invasive subtype, 
previously hidden in the broader phenotypic class of 
invasive tumors.
Subtypes validation in independent datasets
To assess the reproducibility of the three melanoma 
subtypes identified in CCLE, we collected gene expression 
data for 187 melanoma cell lines from five different 
studies (Supplementary Table 1) and integrated them in a 
meta-analysis dataset (Meta-Cell dataset) using ComBat 
to correct for inter-study batch effects (Supplementary 
Figures 2A–2B). The process of subtype validation is 
summarized in Figure 2A. By HC and CHC using the 
RTK/MPSE signature, Meta-Cell dataset was divided 
in three robust clusters (Figure 2B and Supplementary 
Figure 3A). A positive silhouette width was observed 
for 95% of samples (Supplementary Figure 3B). The 
genes contained in the RTK/MPSE signature conserved 
their correlation patterns as 197/210 genes fell into the 
previously defined gene-clusters, indicating a similarity 
between melanoma subtypes defined in CCLE and Meta-
Cell datasets (Figure 2B). SubMap analysis confirmed a 
univocal correspondence between subtypes identified in 
the two independent datasets (Figure 2C).
The same approach was applied to gene expression 
data of 371 metastatic melanoma tissue samples 
collected from 8 public datasets (Meta-Clinical dataset, 
Supplementary Table 1). ComBat adjustment efficiently 
removed the inter-study technical variation that was 
inflated by the merging of datasets profiled with different 
Figure 2: Subtypes validation in independent datasets. (A) Workflow of bioinformatic subtype validation. (B) and (D) Heatmap 
of hierarchical clustering of Meta-Cell (B) and Meta-Clinical (D) datasets according to the RTK/MPSE signature. In each dataset three 
clusters, indicated with letters a, b, c, were identified. (C) and (E) SubMap analysis for similarity assessment between clusters identified 
in Meta-Cell (C) and Meta-Clinical (E) and CCLE subtypes. The colors of the heatmap represent the false discovery rate, reported also 
numerically, which measure the similarity of the subtypes. Meta-Cell and CCLE datasets had 13 cell lines in common: 9 were assigned to 
the same subtype, 3 had an undetermined classification in one of the two datasets and 1 had a discordant classification.
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platforms (Supplementary Figures 2C–2D). Despite only 
154 out of 210 genes of the RTK/MPSE signature were 
available in Meta-Clinical dataset, HC and CHC revealed 
a robust separation of patients in three robust clusters 
(Figure 2D and Supplementary Figure 3C). The majority 
(97%) of samples were correctly assigned to their cluster 
membership as they had a positive silhouette width 
(Supplementary Figure 3D). SubMap analysis revealed 
that the clinical subtypes were identical to those identified 
in CCLE (Figure 2E).
Overall our RTK/MPSE signature enables the 
identification of distinct biological melanoma subtypes in 
a robust and reproducible manner, not only in cell lines but 
also in metastatic melanoma clinical samples.
RTK expression patterns in melanoma subtypes
Differential expression analysis was carried out 
using ANOVA to identify, between the 34 RTKs, those 
with subtype-specific gene expression patterns in both 
CCLE and Meta-Cell datasets (Supplementary Table 3). 
We found 30 RTKs differentially expressed at a false 
discovery rate (FDR) < 0.05 in at least one of the two cell 
line datasets. However, to focus on the most relevant ones 
we selected seven genes (AXL, EGFR, EPHA2, ERBB3, 
MERTK, PDGFRA and PDGFRB) with an FDR < 0.0001 
and a fold-change ≥ 2.5 in at least one of the contrasts, 
in both datasets. Their expression levels according to 
subtypes are shown in Figure 3A for CCLE. The same 
analysis was repeated for the Meta-Clinical dataset 
and the differential expression of 6 of the 7 RTKs was 
validated (FDR < 0.05, Supplementary Table 3), except 
for EPHA2, which however showed a trend of differential 
expression (FDR = 0.052). The fold-changes between 
contrasts observed in Meta-Clinical dataset were lower 
compared to cell lines but gene expression data of clinical 
samples could be affected by a higher noise, due to intra-
tumor heterogeneity and merging of multiple microarray 
platforms.
We then examined the protein expression of these 
seven RTKs and MITF in a panel of 22 patient-derived 
melanoma cell lines (Supplementary Table 4) by Western 
blot analysis (Figure 3B). With a few exceptions, the 
protein expression patterns in these cell lines reflected the 
observations made at the gene level in the three subtypes: 
EGFR and ERBB3 had a mutually exclusive expression 
and all samples with high expression of EGFR and 
absent/low of ERBB3 were a subset of the AXL-positive/
MITF-negative (Invasive) ones. The band intensities 
for each protein were transformed to a numerical score 
corresponding to absent (0), low (1) and intermediate-high 
(2) expression levels. According to HC of these Western 
blot scores, samples were clustered in three distinct groups, 
whose RTK expression pattern resembled EGFRHIGH/
ERBB3LOW-Invasive, EGFRLOW/ERBB3HIGH-Invasive and 
EGFRLOW/ERBB3HIGH-Proliferative subtypes (Figure 3C). 
Western blot analysis of additional RTKs showed that 
ERBB2, DDR1, DDR2 and IGF1R were expressed by 
the majority, but not all cell lines and that MET and KIT 
displayed a more restricted distribution (Supplementary 
Figure 4) highlighting further level of complexity within 
each subtype.
Drug resistance of melanoma cell lines according 
to subtypes
To determine whether our classification could allow 
prediction of melanoma response to drugs, we evaluated 
by ANOVA how melanoma subtypes correlated with drug-
sensitivity data (IC50) in CCLE (Supplementary Table 5). 
When all melanoma cell lines (n = 28) were considered, the 
three subtypes showed a significantly different response 
(FDR < 0.05) to the MEK inhibitor AZD6244 (Figure 4A), 
to the SRC family kinase (SFK)/ABL dual-kinase 
inhibitor AZD0530 and to the ALK inhibitor TAE684 
(Supplementary Table 5). Considering BRAF-mutant 
tumors only (V600E or V600D, n = 19), subtype-specific 
response was still observed for AZD6244 (FDR = 0.030) 
(Figure 4A) and, in addition, for PD-035901 (FDR = 
0.030), a second MEK inhibitor (Supplementary Table 5). 
The most striking drug-response difference was however 
observed for PLX4720 (FDR = 0.001) with EGFRHIGH/
ERBB3LOW-Invasive being the most resistant (Figure 4A). 
Pearson’s correlation between gene expression CCLE 
data and IC50 of PLX4720 across BRAF-mutated 
melanomas confirmed that all seven RTK genes were 
directly (EGFR, AXL, EPHA2, PDGFRA and PDGFRB; r 
between 0.6 and 0.8) or inversely correlated (MERTK and 
ERBB3; r between –0.4 and –0.6) to PLX4720 resistance. 
EGFR was the first RTK and the seventh most positively 
correlated gene (r = 0.845; p-value = 5.34e-06). This 
differential sensitivity to PLX4720 treatment was validated 
in vitro in our panel of patient-derived melanoma cell lines 
after treatment with increasing concentrations of PLX4720 
(Figure 4B). As in CCLE, EGFRHIGH/ERBB3LOW-Invasive 
cells were all highly resistant to PLX4720 (IC50 > 10 μM, 
taken as the maximum value), EGFRLOW/ERBB3HIGH-
Proliferative were sensitive or moderately resistant. The 
AXL-positive EGFRLOW/ERBB3HIGH-Invasive subtype 
showed the same heterogeneous sensitivity observed in 
CCLE, with one cell line being highly resistant and the 
others sensitive or moderately resistant.
The clinical significance of EGFR expression was 
examined in ten surgical specimens of five patients with 
BRAF-mutant melanomas treated at our Institute with 
the BRAFi Vemurafenib (Supplementary Table 6). The 
pre-therapy lesion of patient P3, one of the three patients 
intrinsically resistant to therapy and rapidly progressing 
under treatment, already displayed strong EGFR staining. 
A clear increase in intensity was also found in two 
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progressing metastases taken after therapy (Figure 4C). 
None of these specimens expressed MITF, whereas one of 
the two progressing lesion co-expressed AXL (Figure 4C). 
Pre- or post-therapy melanoma samples from the other 
two unresponsive patients (P2 and P5) and from the 
two responsive ones (P1 and P4), instead, did not have 
detectable staining of EGFR or AXL. All together these 
data indicates that mRNA and protein abundance of a core 
group of RTK are distinguishing traits for the classification 
of melanoma subtypes. Furthermore the RTK/MPSE 
signature allows identification of BRAF tumors 
intrinsically resistant to BRAFi with higher accuracy 
in comparison to the AXL/MITF dual transcriptional 
state. Similarities and differences of the three melanoma 
subtypes are summarized in Table 1.
PI3K/mTOR signaling pathway dependency 
of PLX4720-resistant EGFRHIGH/ERBB3LOW-
Invasive melanoma cells
To explore whether signaling pathway dependencies 
could be similar in the BRAFi intrinsically resistant 
Figure 3: Expression pattern of selected RTKs in melanoma subtypes. (A) Box-plot showing the distribution of log2 expression 
values of RTKs with the most significant differential expression according to melanoma subtypes in CCLE dataset. Statistical analysis by 
ANOVA followed by Tukey’s post-hoc test. (B) Western blot analysis of the seven most relevant RTKs and MITF in the panel of 22 
melanoma cell lines. The BRAF and NRAS mutational status is reported. Since preliminary results indicated that levels of RTKs were not 
affected by culture conditions such as serum-free or serum-containing medium, all analyses were performed by cells grown under standard 
culture conditions. (C) Heatmap representing the hierarchical clustering of protein expression investigated in panel (B) for 22 melanoma 
cell lines. The RTK/MPSE subtype and mutational status are reported and are colored as in (A) and (B) respectively.
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EGFRHIGH/ERBB3LOW-Invasive samples, three out of 
the four BRAFV600E melanoma cell lines representative 
of this subtype were chosen. Me23 and Me36 had high 
expression of EGFR, negligible expression of ERBB3 and 
expressed AXL at different levels. Although grouped in 
the same cluster, Me27 was unique since it co-expressed 
EGFR, AXL and ERBB3. Western blot analysis indicated 
presence of basally phosphorylated (p) EGFR, AXL 
and EPHA2 in all three cell lines (Figure 5A), whereas 
pPDGFRB was detectable in Me36 and pERBB3 in 
Me23. Me27 displayed a faint band in correspondence of 
pPDGFRB and pERBB3. In each cell lines, stimulation by 
a pool of growth factors specific for these RTKs increased 
or induced ex novo phosphorylation of all RTKs except 
ERBB3 for Me36 (Figure 5A). These cell lines were all 
resistant to PLX4720 (Figure 5B).
Pharmacologic blockade of EGFR signaling by 
Gefitinib and Erlotinib was, however, unable to affect 
growth of these cell lines (Figures 5C–5D). Signaling 
blockade of ErbB family (EGFR, HER2, ERBB3) by 
Figure 4: Identification of the EGFRHIGH/ERBB3LOW-Invasive melanoma subtype as intrinsically resistant to 
BRAFi. (A) Box-plot displaying the distribution of IC50 values for AZD6244 and PLX4720 in CCLE dataset according to RTK/MPSE 
subtypes. For AZD6244, data considering all samples (left panel) or BRAF mutated only (middle panel) are shown. For PLX4720, only 
samples with BRAF mutations (V600E or V600D) were selected (right panel). Statistical analysis by ANOVA followed by Tukey’s post-hoc 
test. (B) PLX4720 IC50 values of BRAFV600E melanoma cell lines representative of the different subtypes (green: EGFRHIGH/ERBB3LOW-
Invasive; violet: EGFRLOW/ERBB3HIGH-Invasive; orange: EGFRLOW/ERBB3HIGH-Proliferative). Expression of EGFR, ERBB3, AXL and 
MITF is summarized from Figure 3B. Presence of the corresponding protein is indicated by full colored boxes; absence as empty box. For 
ERBB3, shaded boxes indicate low expression. (C) EGFR, AXL and MITF staining in serial sections of pre- and post-treatment melanoma 
specimens from a patient intrinsically resistant to Vemurafenib treatment (Patient P3). 20x magnification. Scale bar = 100 μm.
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Canertinib, of EGFR and HER2 by Lapatinib and of 
PDGFR by Crenolanib could be effective only at high 
dose (Figures 5E–5G). None of these drugs, with the 
exception of Caneternib and Crenolanib on Me23, 
showed a synergistic effect with PLX4720 (data not 
shown). Two out of the three melanoma lines (Me27 
and Me36) were instead sensitive, at low μM dose, to 
Dasatinib, a multikinase inhibitor [30] (Figure 5H). In 
addition, the PLX4720/Dasatinib combination was able 
to reduce growth of Me23 and to further enhance cell 
growth inhibition of Me27, in comparison to both drugs 
alone (Figure 6A) and the effect was strongly synergistic 
(Figure 6B). To identify the signaling pathway/s inhibited 
by the combination of PLX4720 and Dasatinib we 
examined, by Western blot, the activation of components 
of PI3K/AKT/mTOR, ERK/MAPK and SRC/FAK/
Paxillin, following single or combined drug treatments 
(Figure 6C). Overall, we observed that the PLX4720/
Dasatinib combination was more effective in abrogating 
or reducing, in Me23 and Me27, levels of phosphorylated 
(p) ribosomal protein S6, a marker of mammalian target 
of rapamycin complex 1 (TORC1) activity [31], at both 
pS6S235–236 and pS6S240–242 sites. The effect of the drug 
combination in comparison to single drugs was instead 
similar for Me36 that displayed similarly sensitivity 
to Dasatinib and PLX4720/Dasatinib combination 
(Figure 6C). The effect of Dasatinib alone on pS6 was 
also associated to the degree of Dasatinib sensitivity 
(Figure 6C). All together, these findings suggested a 
convergence of the combined treatment on suppression 
Figure 5: RTK activation and effect of RTKs inhibitors on BRAFV600E EGFRHIGH/ERBB3LOW-Invasive melanoma cell 
lines. (A) Basal RTK and ligand induced phosphorylation. Melanoma cell lines were cultured overnight in the absence of serum and 
stimulated for 10 minutes with serum-free medium or with medium containing a pool of growth factors: EGF, NRG1-β1/HRG1-β1, PDGF 
(all at 100 ng/ml) and GAS6 500 ng/ml. All RTKs were basally phosphorylated, although at different level, in Me27; all, except PDGFR, in 
Me23; all, except PDGFR and ERBB3, in Me36. Ligand stimulation increased or induced phosphorylation of all RTKs with the exception 
of ERBB3 for Me36. (B–H) Representative growth curves, based on alamarBlue viability assays, of Me23, Me27 and Me 36 following a 
72 h treatment with the indicated inhibitor. Means and standard deviations of three replicates are shown. Normalized viability (%) is relative 
to vehicle-treated (DMSO) control cells.
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of TORC1 activity. As expected, Dasatinib completely 
abrogated pSRC and downstream targets, pPaxillin and 
pFAK in all three cell lines and reduced pAKT levels in 
Me27 and Me36. PLX4720 reduced pERK in Me23 and 
Me27. The PLX4720/Dasatinib combination was unable to 
modulate these molecules any further, indicating that they 
were not a necessary requirement to allow a synergistic 
growth inhibitory effect to occur.
To prove that PI3K/mTOR signaling inhibition 
could be relevant for these intrinsically resistant cells, 
we used BEZ235, a selective inhibitor of the class I 
phosphoinositide 3-kinase (PI3K) enzymes and mTORC1 
and 2, GDC-0941, a PI3K inhibitor (PI3Kα/δ), and 
AZD8055, an inhibitor of mTORC1 and 2. BEZ235 and 
AZD8055 potently inhibited the in vitro growth of all three 
melanoma cell lines (Figure 7A and 7B), whereas GDC-
0941 was less potent (Figure 7C). Inhibition of RAF/
MAPK/ERK pathway by PLX4720 exerted no further 
effect on cell growth of two out of three cell lines. Only 
on Me23, the combination of PLX4720 with GDC-0941, 
or AZD8055 achieved synergistic growth inhibitory effect 
indicating that, for this particular melanoma, concurrent 
suppression of RAF/MAPK/ERK pathway is necessary 
to affect growth when only PI3K or mTOR signaling 
is abrogated. Taken together, these results indicate that 
blockade of upstream RTKs can achieve only modest 
growth inhibitory activity in PLX4720-resistant cells of 
the EGFRHIGH/ERBB3LOW-Invasive subtype, whereas their 
Figure 6: Effect of Dasatinib and Dasatinib/PLX4720 combination on BRAFV600E EGFRHIGH/ERBB3LOW-Invasive 
melanoma cell lines. (A) Dose-response curves to Dasatinib, PLX4720 and their combination. Dasatinib IC50 was 8.54 μM for Me23, 
0.6 μM for Me27 and 0.41 μM for Me36. Data shown are means and standard deviations of three replicates. (B) Drug interaction analysis 
by Chou and Talalay method. Shown are color-coded fraction affected values (effect, E) and combination indexes (CI) for Me23 and Me27 
at the indicated drug combination doses. The color-code is shown at the bottom of the panel. (C) Effects of a 24 h treatment with PLX4720 
(PLX, 1 μM), Dasatinib (Das, 0.25 μM) and their combination (PLX+Das) on phosphorylation of signaling molecules in Me23, Me27 and 
Me36. The combination between PLX4720 and Dasatinib reduced phosphorylation of S6 (S235–236 and S240–244) in comparison to 
single drugs when growth inhibitory effect was synergistic (Me23 and Me27). Controls are vehicle (DMSO) treated cells.
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growth could be affected when both PI3K and mTORC1/2 
are effectively targeted, even without simultaneous 
inhibition of RAF/MAPK/ERK pathway.
DISCUSSION
In this study, we explored whether expression 
levels and types of RTKs, frequently identified as targets 
of negative feedback loop release and involved in drug 
resistance mechanisms [21–28, 32–34], could identify 
subtypes differing in terms of sensitivity to BRAFi. 
Hierarchical clustering was therefore used to examine 
RTK gene expression similarities among a high number 
of samples (245 melanoma cell lines and 371 clinical 
samples). Taking into account the previously described 
MPSE phenotypes [17], we identified three stable 
melanoma subtypes. Our classification significantly 
improves detection of intrinsically resistant melanoma 
cells. Indeed, melanomas belonging to one of the two 
previously described divergent phenotypes [12–17], 
displaying high levels of AXL, were recently shown to 
exhibit intrinsic resistance to MAPK-pathway inhibitors 
[20]. However, as shown in CCLE dataset and by drug 
sensitivity assays on melanoma cell lines, melanomas with 
high expression of AXL include both resistant and sensitive 
tumors. Instead, our newly defined EGFRHIGH/ERBB3LOW-
Invasive subtype is composed only of resistant tumors.
EGFR has been involved in adaptive and acquired 
resistance of melanoma to BRAFi. In one study, 6 post-
treatment biopsies from 16 patients who developed 
resistance to BRAFi or MEKi expressed EGFR [28]; in 
another, EGFR was hyperphosphorylated in 4 post-therapy 
lesions from 5 relapsed patients [23]. The first study 
hypothesized that increased EGFR could be the result 
of an adaptive response of melanoma cells occurring in 
presence of the drug and due to the activation of TGFβ 
signaling following loss of the transcription factor 
SOX10 [28]. Knockdown of SOX10 led to increased 
Figure 7: PI3K/mTOR inhibitors reduce viability of BRAFV600E EGFRHIGH/ERBB3LOW-Invasive melanoma cell 
lines. Dose-response curves of Me23, Me27 and Me36 to BEZ235, GDC-0941, AZD8055 alone or in combination with PLX4720 (1 μM). 
Data shown are means and standard deviations of three replicates. Normalized viability (%) is relative to vehicle-treated (DMSO) controls. 
For each cell line, IC50 values of PI3K and/or mTOR inhibitors are listed above each graph.
Oncotarget5129www.impactjournals.com/oncotarget
EGFR expression and to a concomitant decrease of MITF 
[28]. We here describe that these features, expression of 
EGFR, lack of MITF and SOX10, are inherent and occurs 
independently of drug selection in EGFRHIGH/ERBB3LOW-
Invasive melanomas. Both MITF and SOX10 are included 
in the RTK/MPSE signature (cluster 1) and are down-
regulated in this subtype. Our in vivo evidence of EGFR 
expression in both pre-therapy and post-therapy lesions of 
one out of three unresponsive patients, highlight the need 
to assess expression of EGFR and other RTKs in pre-and 
post-therapy lesions of a larger cohort of BRAF-mutant 
patients with different response to BRAFi treatment. These 
studies will inform on the value of EGFR and other RTKs 
as biomarkers to identify BRAFi intrinsically resistant 
tumors and will allow evaluation of their frequency at all 
stages of resistance from intrinsic to adaptive and acquired.
In some instances but not in others, mechanisms 
of resistance involving RTKs can be counteracted by 
inhibition of RTKs often cooperating with PLX4720 to 
inhibit growth of resistant cells in vitro and in vivo [20, 
23, 27, 28]. In our three melanoma cell lines representing 
the PLX4720-resistant EGFRHIGH/ERBB3LOW-Invasive 
subtype, inhibition of single RTKs had limited efficacy 
alone or in combination with PLX4720. Among the drugs 
tested, only Dasatinib was effective and combination of 
PLX4720 with Dasatinib resulted in a synergistic shifting 
of the dose response even in Me23, which was resistant 
to both single drugs. Dasatinib has a wide kinase profile 
and targets PDGFRB, EPHA2, KIT, DDR1 and DDR2, 
in addition to SRC family kinases and BCR–ABL [30]. 
Inhibition of these RTKs may be particularly relevant to 
counteract the release of negative feedback loops with 
the consequent activation of various signaling proteins 
[32–34]. The synergy between PLX4720 and Dasatinib 
converged on suppression of pS6, a marker mTORC1 
activity. Combined inhibition of PI3K and MTORC1/2, an 
attractive pathway target in melanoma [35], by BEZ235, 
even without the addition of PLX4720, achieved strong in 
vitro inhibition in these intrinsically resistant cells.
In conclusion, our results describe molecular 
features allowing identification of a melanoma subtype 
intrinsically resistant to BRAFi. Further characterization 
of this subtype may allow definition of a set of biomarkers 
that, together with RTKs, will aid the prediction of 
intrinsic resistance. In addition, this study highlights the 
need to understand signaling networks that, in addition to 
the one here identified, could guide the choice of effective 
treatments for this subtype of unresponsive patients.
MATERIALS AND METHODS
Gene expression data
The discovery dataset was built starting from the 
Cancer Cell Line Encyclopedia (CCLE) [29]: raw CEL files 
(Affymetrix U133 Plus 2.0 array) for 58 melanoma cell 
lines were obtained from the CCLE database (http://www.
broadinstitute.org/ccle/home); mutational status of BRAF 
was retrieved from CCLE_hybrid_capture1650_hg19_
NoCommonSNPs_NoNeutralVariants_CDS_2012.05.07.
maf file; drug sensitivity data were extracted from CCLE_
NP24.2009_Drug_data_2012.02.20.csv file.
The Meta-Cell dataset was composed of five studies 
[13, 36–39] profiled with Affymetrix U133 Plus 2.0 array, 
for a total of 188 melanoma cell lines. The Meta-Clinical 
dataset was composed of eight studies [40–45] for a total 
of 378 metastatic melanoma samples profiled with five 
different platforms. Raw data were downloaded from 
NCBI Gene Expression Omnibus database [46] (GEO, 
http://www.ncbi.nlm.nih.gov/geo/).
Gene expression data processing
For Affymetrix datasets, raw data were pre-
processed using frozen RMA [47] as implemented in 
the frma package of Bioconductor [48]. To distinguish 
expressed and silenced probe sets we applied the barcode 
[49] function of frma package. For Illumina datasets, 
raw data were log2 transformed and normalized using 
the robust spline normalization method implemented in 
the lumi package [50]. Quality Control was applied to 
each dataset independently on raw and normalized data. 
Independent datasets composing the Meta-Cell and Meta-
Clinical datasets were normalized separately and merged 
using ComBat [51]. For identification of the RTK/MPSE 
signature and for statistical analysis all datasets were 
collapsed at the gene level selecting the probe with highest 
variability according to inter-quartile range.
Identification of melanoma subtypes and 
subtypes-specific gene signature
Identification of sample clusters according to RTKs 
expression profiles was achieved using agglomerative 
hierarchical clustering with average linkage and 
1-Pearson’s correlation coefficient as distance measure. 
Cluster stability was determined by consensus hierarchical 
clustering [52], with average linkage, 1-Pearson’s 
correlation as distance and a sub-sampling ratio of 
features of 0.8 for 1000 iterations. Silhouette width [53] 
was calculated to identify representative samples for 
each class. Phenotype prediction essentially followed the 
described classification method [17] except for Pearson’s 
correlation coefficient (r) cut-off:
Invasive: rinv ≥ 0.4 and |rinv – rprol| ≥ 0.4
Proliferative: rprol ≥ 0.4 and |rinv – rprol| ≥ 0.4
Undetermined: rprol < 0.4 and rinv < 0.4 or 
|rinv – rprol| ≥ 0.4
ClaNC algorithm [54] was used to select 
discriminating genes among melanoma subtypes. The 
number of genes tested for each class varied from 1 to 
200 and the optimal gene signature was selected as that 
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with the lowest number of genes and lowest error rate, 
assessed by five-fold cross-validation. SubClass mapping 
[55], implemented in the SubMap module version 3 of 
GenePattern software [56], was applied to assess the 
similarity between subtypes in discovery and validation 
datasets. Functional analysis was performed by IPA 
(Ingenuity® Systems, http://www.ingenuity.com).
Cell lines
The study was conducted according to Declaration of 
Helsinki Principles and following Institutional guidelines. All 
primary and metastatic melanoma cell lines were established 
in vitro from surgical specimens of cutaneous malignant 
melanomas; their origin, mutational status and membership 
to molecular subtypes identified in this study, are listed in 
Supplementary Table 4. Molecular and biological features of 
these cell lines and methods for identification of mutations 
in BRAF, NRAS, PTEN and p53 genes and for cell 
maintenance have been previously reported [19, 57]. Identity 
of the cell lines was verified by short tandem repeat profiling 
from early passage cells which are maintained as frozen 
stocks and used for the experiments. All lines were tested 
for the absence of Mycoplasma contamination by Hoechst 
33258 (Sigma-Aldrich, St. Louis, USA).
Inhibitors
PLX4720, AZD8055, GDC0941, BEZ235, Canertinib, 
Erlotinib (Tarceva), Gefitinib (Iressa), Crenolanib, Lapatinib 
(Tykerb) and Dasatinib (Sprycel) (all from Selleck 
Chemicals, Houston, TX, USA) were diluted in DMSO at 
10 mM/ml and stored at −20°C until use; when added to 
cell cultures, the final DMSO concentration was 0.25–0.5%.
Pharmacological growth inhibition assays
Cultured melanoma cells were seeded into 48-well 
plates. Twenty-four hours after seeding, serial dilutions 
of individual drugs, drug combinations and/or vehicle 
(DMSO), as indicated in the text, were added to achieve 
the desired final concentrations. The doses were 0.004, 
0.016, 0.063, 0.25, 1, 4 μM for AZD8055; 0.004, 0.016, 
0.063, 0.25, 1, 4, 16 μM for PLX4720 and Dasatinib; 
0.063, 0.25, 1, 4, 8, 16 μM for Erlotinib and Gefitinib; 
0.25, 0.5, 1, 2, 4, 8, 16 μM for GDC0941, Crenolanib and 
Lapatinib; 0.5, 1, 2, 4, 8, 16 μM for Canertinib; 0.0016, 
0.008, 0.04, 0.02, 1, 5 μM for BEZ235. For growth 
inhibition, cells were incubated for 72 h and cell viability 
determined using alamarBlue assay (Bio-Rad, Hercules, 
CA, USA) as previously described [19]. For Western blot, 
cells were processed after 24 hr incubation.
Growth factor pool stimulation
After an overnight starvation, melanoma cells were 
treated for 10 min with serum-free medium containing or 
not a pool of human growth factors consisting of 100 ng/
ml EGF (Cell Signaling, Danvers, MA, USA), 500 ng/ml 
recombinant (r) Gas6, 100 ng/ml rNRG1-β1/HRG1-β1 
(R&D Systems, Minneapolis, MN, USA) and 100 ng/ml 
PDGF (Sigma-Aldrich, St.Louis, MO, USA).
Western blotting
Untreated or treated melanoma cells were processed 
as described [19] using the primary antibodies listed in 
Supplementary Table 7.
Immunohistochemistry
Formalin-fixed paraffin-embedded tissues of 
melanoma samples were sectioned at 1 μm slide. 
Immunohistochemical detection was performed 
as described [19, 58] using antibodies listed in 
Supplementary Table 7. Slides were scored for staining 
by a dermatopathologist blinded to clinical outcome and 
were imaged with a digital camera (AxioCamMrC5, Zeiss, 
Oberkochen, Germany) using an Axiovert 100 microscope 
(Zeiss) and a 20x objective.
Statistical analysis and drug synergy testing
Differences in expression level of RTKs and 
differences in IC50 values of PLX4720 among subtypes 
were assessed by ANOVA p-values adjusted for multiple 
testing using the Benjamini-Hochberg false discovery 
rate. Tukey’s post-hoc analysis was performed only when 
the overall adjusted p-values was < 0.05. Association 
between categorical variables was carried out using 
Fisher’s exact test. All statistical tests were two-sided. 
Correlation between variables was calculated using 
Pearson’s correlation coefficient. Analyses were conducted 
in R environment version 3.0.2. For pharmacological 
growth inhibition assays: generation of fitted lines using 
the four-parameter nonlinear regression with a sigmoidal 
dose-response (variable slope) and calculation of IC50 
values of dose-response curves were done using Prism v 
5.0 software (GraphPad Software, La Jolla, CA, USA); 
the combination index (CI) between pharmacological 
inhibitors was established by the Chou and Talalay method 
[59] using CompuSyn software (Biosoft, Cambridge, UK). 
CI < 1 was considered synergism.
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